Zorevunersen

RNA / oligonucleotide

Also known as STK-001

Phase 3underway

Evidence outlook · registrational

Dravet Syndrome: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2027-03.

Company guidance: topline data expected Q3 2027 (Stoke Therapeutics, Inc., 3 Aug 2026). “Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027–” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Dravet Syndrome
Phase 2 (1)
Dravet Syndrome
NCT04740476 · Stoke Therapeutics, Inc
2021-01-20 – 2029-03-31 · Dravet Syndrome
What this study did
Phase 1/2 (1)
Dravet Syndrome

Competitive landscape

Other SCN1A mRNA drugs

ION337. Compare all 2 SCN1A mRNA drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Dravet Syndrome: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zorevunersen: this drugPhase 3RNA / oligonucleotideSCN1A mRNAWeak signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
NCT02926898: Change in monthly convulsive seizure frequency over titration plus maintenance, fenfluramine 0.4 mg/kg/day (n=43) vs placebo (n=44), in Dravet syndrome on stiripentol-inclusive regimens: 54.0% greater reduction with fenfluramine (95% CI 35.6% to 67.2%); ANCOVA p<0.001 (CT.gov posted analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (Kanbis)
Phase 2(overall)
Small moleculecannabinoidnot yet gradedNo reviewed efficacy summary in this indication
Huperzine A (SPN-817)
Phase 2(overall)
Small moleculeAcetylcholinesterasenot yet gradedNo reviewed efficacy summary in this indication
ION337
Phase 1/2(overall)
RNA / oligonucleotideSCN1A mRNA
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zorevunersen to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
Phase 3Dravet SyndromeActive not recruiting
Est. primary completion 2027-03 · NCT06872125 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 2Dravet SyndromeActive not recruiting
Est. primary completion 2029-03-31 · NCT04740476 · CT.gov ↗
What to watch

See the full readout calendar ↗